Dr. Ghassan E. Hadi, MD

Dr. Hadi practices at Ghassan Hadi MD Inc in Upland, California.

Dr. Hadi's NPI, 1558497891, was assigned on February 23, 2007. Dr. Hadi graduated from Keck School of Medicine of USC in 1999. Dr. Hadi holds California license A52260.

Dr. Hadi's primary practice is Ghassan Hadi MD Inc, at 1060 E Foothill Blvd, Upland, CA 91786 in San Bernardino County. The practice phone is (909) 981-8904.

Dr. Hadi's primary practice is Ghassan Hadi MD Inc in Upland, California. Dr. Hadi is also affiliated with San Antonio Regional Hospital. The medical group on file is Ghassan Hadi, MD. Dmand AI also links Dr. Hadi to 2 more hospitals, 5 skilled nursing facilities, 1 group practice or clinic, 1 home health agency, 1 hospice and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hadi practices, 12 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Hadi's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Hadi is licensed in California.

Dmand AI lists acute diabetes, acute kidney failure, acute sinusitis, acute skin infection, anemia, aneurysm, arthritis and asthma among the conditions Dr. Hadi treats.

CMS data shows 2,111 Medicare services from Dr. Hadi across 7 procedure codes in 2024, for 324 Medicare patients. Medicare paid $196,415 for them.

CMS counts 324 Medicare patients who saw Dr. Hadi in 2024. The largest group is 65 to 74, with 115 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 52% are also on Medicaid. Their average risk score is 2.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hadi's median patient age at 65, with 52% women.

In 2024, Dr. Hadi wrote 10,225 Medicare Part D claims for 443 patients. 83% of them were for generic drugs. CMS names the drug for 9,161 of them, across 180 drugs with 11 or more claims each, at $678,727 in total drug cost. In 2023, CMS named 8,441 claims across 171 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Hadi for performance year 2024, reported individually. Dr. Hadi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 5 papers to Dr. Hadi, published from 2011 to 2016. 2011 was the busiest year, with 2. The most frequent topics are Analgesics, Opioid, Body Temperature and Carbon Dioxide. Dr. Hadi has published most often in Cochrane Database Syst Rev. Dr. Hadi's most frequent co-authors are Shahzeer Karmali, MD and Jerry Dang, FRCSC, MD, PhD.

Dmand AI links Dr. Hadi to 3 clinical trials, 2 of them phase 3 studies. Conditions studied include Constipation, Osteoarthritis, Knee and Renal Insufficiency, Chronic. Open Payments lists research payments to Dr. Hadi that name 1 trial.

CMS Open Payments shows 55 general payments to Dr. Hadi from 27 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $281. It also lists 16 research payments totaling $95,693 from 2016 to 2022, naming 1 clinical trial.

Dr. Hadi graduated from Keck School of Medicine of USC in 1999.

Dr. Hadi is in network with 10 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.